¿Cuáles son las pautas para la insulinización y manejo de la insulina?
1. Criterios de Insulinizacion. 2. Tipos de Insulina. 3. Esquemas de Insulina. 4. Como se inicia el tratamiento con Insulina y como se titula? 5. Como se avanza al siguiente esquema? 6. Efectos adversos de tratamiento con insulina. 7. Educacion al paciente: Traslado de farmacia al hogar. Tecnica de Administracion. Almacenamiento. Disposicion de desechos. Signos de hipoglucemia.
Summary
Below is a concise, clinically oriented overview of insulin initiation and management in type 2 diabetes, aligned with major guidelines (ADA, EASD, AACE). It covers criteria to start insulin, insulin types, regimens, initiation and titration, treatment progression, adverse effects, and key points for patient education.[1]``[2]
1. Criteria for Starting Insulin in Type 2 Diabetes
Insulin is indicated when any of the following apply:[1]``[2]
-
Severe hyperglycemia at diagnosis or follow‑up
- A1c ≥10% (≥86 mmol/mol) and/or
- Fasting plasma glucose ≥250–300 mg/dL (≥13.9–16.7 mmol/L), or
- Random glucose ≥300 mg/dL with symptoms (polyuria, polydipsia, weight loss, ketosis).
[1]
-
Symptomatic or catabolic state
- Weight loss, ketosis, ketonuria, or hyperosmolar state.
- Acute illness, surgery, myocardial infarction, stroke, pregnancy.
-
Failure of oral/GLP‑1 therapy
- A1c remains above individualized goal (commonly >7–8%) despite maximally tolerated oral agents and/or GLP‑1RA for 3–6 months.
[1]``[2]
- A1c remains above individualized goal (commonly >7–8%) despite maximally tolerated oral agents and/or GLP‑1RA for 3–6 months.
-
Contraindications/intolerance to multiple non‑insulin agents
- Advanced CKD or hepatic insufficiency limiting oral options.
Insulin can be temporary (e.g., during acute illness) or long‑term depending on response and underlying β‑cell reserve.[1]
2. Types of Insulin (Clinical Classification)
A. Basal (Long‑acting) Insulin
Provides relatively constant background insulin:
- NPH (isophane) – intermediate‑acting (peak ~4–8 h, duration ~12–18 h).
- Long‑acting analogs:
- Glargine (U100, U300),
- Detemir,
- Degludec (ultra‑long).
Clinical notes:
- Long‑acting analogs have flatter profiles and less nocturnal hypoglycemia than NPH.
[3]``[4] - Degludec and glargine U300 allow more flexible dosing time.
[3]
B. Prandial (Rapid‑acting) Insulin
Covers meal‑related glucose rises:
- Rapid‑acting analogs: lispro, aspart, glulisine; onset ~10–20 min, peak ~1–3 h, duration 3–5 h.
[3] - Ultra‑rapid analog formulations (e.g., faster‑acting aspart) with slightly faster onset.
C. Premixed Insulins
Fixed combinations of basal (NPH or analog) + prandial component:
- Human premix (e.g., 70/30 NPH/regular).
- Analog premix (e.g., 70/30 or 75/25 NPH‑analog mix).
Useful when:
- Regular meal pattern.
- Simpler regimen is needed and full basal‑bolus is not feasible.
[1]
D. Concentrated Insulins
Same type but higher concentration (e.g., U200, U300, U500) used for insulin‑resistant patients needing high doses. Require careful patient education.
3. Common Insulin Regimens (“Esquemas”)
3.1 Basal‑Only Regimen
- Once‑daily basal insulin (evening or morning).
- Typically combined with oral agents ± GLP‑1RA.
[1]``[2] - First‑line insulin approach in most T2D patients.
3.2 Basal‑Plus (Basal
- 1 Mealtime Dose)
- Basal insulin + one prandial dose at the largest meal or the meal with greatest postprandial excursion.
- Step between basal‑only and full basal‑bolus.
[2]
3.3 Basal‑Bolus (Multiple Daily Injections)
- Basal insulin once daily + rapid‑acting insulin before each main meal (typically 3 times/day).
- Offers greatest flexibility and best mimicry of physiologic insulin but requires more injections and monitoring.
[1]
3.4 Premixed Regimen
- Twice‑daily premixed insulin (before breakfast and dinner).
- Sometimes 3‑times daily in selected cases.
- Less flexible than basal‑bolus; risk of hypoglycemia if meals skipped or delayed.
Choice depends on:
- A1c pattern (fasting vs postprandial elevation).
- Meal schedule.
- Patient ability for SMBG and carb counting.
- Cost and access.
[1]``[2]
4. How to Start Insulin and How to Titrate
4.1 Start Basal Insulin (Most Common in T2D)
Guideline‑based options (reasonably equivalent):[1]``[2]
- Fixed dose: 10 units once daily.
- Weight‑based: 0.1–0.2 units/kg/day (higher if A1c markedly elevated, e.g., 0.2–0.3 U/kg).
Continue metformin; consider keeping SGLT2i and/or GLP‑1RA if tolerable, and usually stop or reduce secretagogues (sulfonylureas) to reduce hypoglycemia risk.[1]
Basal Titration
- Aim for fasting plasma glucose (FPG) ~80–130 mg/dL (4.4–7.2 mmol/L), individualized.
[1] - Typical titration:
- Increase by 2 units every 3 days if FPG > goal.
- Or 10–15% of total daily dose every 3–7 days.
- If FPG <70 mg/dL (3.9 mmol/L) or symptomatic hypoglycemia:
- Reduce basal dose by 10–20% and reassess SMBG, diet, and other drugs.
[1]
- Reduce basal dose by 10–20% and reassess SMBG, diet, and other drugs.
Use structured self‑monitoring (e.g., FPG daily or several times/week).
4.2 Initiate Prandial Insulin (Basal‑Plus)
Add rapid‑acting insulin before the largest meal when:
- A1c remains above goal despite FPG at target (suggesting postprandial hyperglycemia).
[1]``[2]
Starting dose:
- 4 units, or
- 0.1 U/kg, or
- 10% of basal dose, before the largest meal.
[1]
Titration:
- Adjust by 1–2 units (or ~10–15%) twice weekly based on 2‑hour postprandial or next premeal glucose, aiming for ~100–180 mg/dL (5.6–10 mmol/L), individualized.
[1]
4.3 Initiate Basal‑Bolus
Indicated when:
- A1c remains above target despite optimized basal‑plus OR
- Very high A1c and symptomatic hyperglycemia at presentation (catabolic state).
[1]``[2]
Common approach:
- Total daily dose (TDD): 0.3–0.5 U/kg/day (lower in older/frail, higher if very obese or on steroids).
- Split: ~50% basal, 50% prandial divided across meals.
- Titrate basal to FPG target and each bolus according to pre‑ and post‑meal glucose.
5. How to Progress to the Next Regimen
Use a stepwise approach guided by residual hyperglycemia pattern.[1]``[2]
-
From oral agents → Basal insulin
- If FPG elevated and A1c high despite oral therapy.
-
From basal‑only → Basal‑plus or Premix
Consider stepping up when:- Basal dose >0.5 U/kg/day and FPG at goal, but A1c still above target.
- CGM/SMBG shows normal fasting but high postprandials.
Options: - Convert to basal‑plus (add 1 mealtime injection) or
- Switch to premixed insulin twice daily if simpler regimen needed.
[1]
-
From basal‑plus → Full basal‑bolus
- Add prandial insulin to second then third main meal if A1c still not at goal.
-
From premix → Basal‑bolus
- If control inadequate and patient can manage more injections and monitoring.
At each step, reassess hypoglycemia risk, adherence, injection technique, diet, and comorbidities before simply increasing dose.[1]
6. Adverse Effects of Insulin Therapy
6.1 Hypoglycemia
- Most important and common adverse effect.
- Symptoms: sweating, tremor, palpitations, hunger, anxiety, confusion, visual changes; in severe cases seizures, loss of consciousness.
- Risk factors: excess dose, missed/delayed meals, exercise without adjustment, renal insufficiency, alcohol, older age, use with sulfonylureas.
[1]``[3]
Long‑acting analog basal insulins are associated with less nocturnal and overall hypoglycemia vs NPH in RCTs.[3]``[4]
6.2 Weight Gain
- Insulin has anabolic effects and reduces glucosuria, typically causing weight gain of several kg over months.
- Mitigation: dietary counseling, physical activity, combining with agents associated with weight neutrality or loss (metformin, SGLT2i, GLP‑1RA).
[1]``[2]``[5]
6.3 Injection‑Site Issues
- Pain, bruising, lipohypertrophy or lipoatrophy (if sites not rotated).
- Rare allergic reactions or local infection.
6.4 Other
- Edema (usually mild, transient).
- Hypokalemia in overdose or in specific contexts (e.g., combined with high‑dose β‑agonists or in DKA treatment).
7. Patient Education (Key Points)
Education is essential for safety and effectiveness.[1]``[2]``[6]
7.1 From Pharmacy to Home (Transport)
- Keep insulin between ~2–8 °C (refrigerated) before first use.
- During transport:
- Avoid freezing and excessive heat (>30 °C).
- Use insulated bag or cool pack if travel is long or weather hot (ensure insulin is not directly touching ice).
7.2 Storage at Home
- Unopened vials/pens: in refrigerator (2–8 °C), not in freezer.
- In‑use vial/pen:
- Most products can be kept at room temperature (up to ~25–30 °C, per specific product insert) for typically 28 days (some longer); label and follow product‑specific instructions.
[6] - Protect from direct sunlight and heat.
- Most products can be kept at room temperature (up to ~25–30 °C, per specific product insert) for typically 28 days (some longer); label and follow product‑specific instructions.
- Discard insulin that:
- Has been frozen,
- Looks cloudy or has particles (for clear insulins),
- Is past expiration or beyond recommended in‑use period.
7.3 Injection Technique
Key teaching points:
-
Preparation
- Wash hands.
- Check insulin type, dose, and expiration.
- For NPH or premix: gently roll/tilt pen or vial to resuspend (do not shake vigorously).
-
Site Selection
- Preferred: abdomen (avoiding 2‑inch circle around navel), outer thigh, upper buttocks, posterior upper arm.
- Rotate within and between sites to avoid lipohypertrophy.
-
Technique
- Use appropriate needle length (usually 4–6 mm for pens in adults).
- Pinch skin if very lean; insert needle at 90° (or 45° for longer needles or very thin patients).
- Inject slowly; count 10 seconds before removing pen needle to ensure full dose.
-
Frequency of Changing Needles
- Use a new needle for each injection to reduce pain, clogging, and lipohypertrophy.
Provide demonstration and return‑demonstration; written/visual materials help reinforce learning.[6]
7.4 Disposal of Sharps and Waste
- Do not discard needles in regular household trash.
- Place used needles and lancets in puncture‑resistant container (e.g., FDA‑cleared sharps container or heavy plastic bottle with secure lid).
- Follow local regulations for sharps disposal (pharmacy/clinic drop‑off, community sharps program, etc.).
7.5 Recognition and Management of Hypoglycemia
Teach patients and family:
Typical symptoms
- Autonomic: sweating, tremor, palpitations, hunger, anxiety.
- Neuroglycopenic: confusion, difficulty speaking, blurred vision, drowsiness, behavior changes.
“15‑15 Rule” for Mild–Moderate Hypoglycemia
- If blood glucose <70 mg/dL (3.9 mmol/L) and patient is awake and able to swallow:
- Take 15 g of fast‑acting carbohydrate (e.g., 3–4 glucose tablets, 120–150 mL regular soda or juice).
- Re‑check glucose in 15 minutes.
- If still <70 mg/dL, repeat.
- Once >70 mg/dL and next meal is >1 hour away, take longer‑acting carbohydrate (e.g., snack with starch + protein).
Severe Hypoglycemia (not fully conscious or cannot swallow)
- Caregivers should be trained to:
- Use glucagon (injection or nasal) if available.
- Call emergency services.
- After any severe episode, dose adjustment and regimen review are required.
[1]
If you share a specific patient profile (age, comorbidities, A1c, current therapy, renal function), I can outline a tailored algorithm: when to start insulin, which regimen to choose first, and how to titrate safely in that context.
[1] American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. [1]
[2] Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022 consensus report by the ADA and EASD. Diabetologia. [2]
[3] Rosenstock J, et al. Reduced hypoglycemia with insulin glargine vs NPH in type 2 diabetes. Arch Intern Med. [3]
[4] Marso SP, et al. Degludec vs Glargine in type 2 diabetes (DEVOTE). N Engl J Med. [4]
[5] Nauck MA, et al. Weight considerations in type 2 diabetes management. Lancet. [5]
[6] Heinemann L, et al. Insulin injection technique: recommendations. Mayo Clin Proc. [6]
Fuentes
- https://diabetesjournals.org/care/article/47/Supplement_1/S1/153308
- https://link.springer.com/article/10.1007/s00125-022-05787-2
- https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/217514
- https://www.nejm.org/doi/full/10.1056/NEJMoa1615692
- https://www.sciencedirect.com/science/article/pii/S0140673613618885
- https://www.mayoclinicproceedings.org/article/S0025-6196(16)30344-3/fulltext
Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.